Abstract
Background and Aims: Low density lipoprotein cholesterol [LDL-c] is a major modifiable cardiovascular disease [CVD] risk factor. A 1% reduction in LDL-c lowers CVD mortality by 2-4%. Proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9I) therapy achieves 50-60% reduction of LDL-c and is indicated in patients with high CVD risk when statins are not tolerated or ineffective.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
